skin cancer

Revised tumor classification for head and neck CSCCAJCC updates classifications for head and neck cutaneous squamous cell carcinoma. AJCC 8 expands criteria for cases that now qualify to be T3. Now, T3 and T4 capture more poor outcomes.
Ruler is better than eye for pigment measurePhysicians should measure pigmented lesion diameter with a ruler rather than estimating via landmarks or the naked eye, a study shows.
Guide to ID at-risk patientsA recent study explored varying statistical approaches to a metastatic risk model for identifying SCC tumors at high risk of metastasis. Researchers identified six risk factors.
Revised melanoma staging criteriaStaging system is derived from a new dataset of patients from 10 cancer centers around the world. Dermatologists should consider AJCC tumor characteristics as well as other factors in risk assessment, counseling, and follow-up plans for patients. Update takes effect in January 2018.
Repurposed antifungal exhibits promising results
Repurposed antifungal exhibits promising resultsA novel oral formulation of itraconazole designed to improve bioavailability is leveraging its activity as a Hedgehog pathway inhibitor to provide a low toxicity, effective treatment for patients with BCC Nevus Syndrome. Data show potential for rapid therapeutic benefit.
SLNB for melanomaBiopsy can differentiate risk level for patients, but selectively indicated
Melanoma tumor suppressorA known oncogene previously associated with carcinomas of the breast, liver, ovaries, and colon appears to suppress the growth of melanoma cells, a team of researchers reported recently in Cell Reports.
Kyocera develops image recognition technology for skin disease identificationKyocera Communication Systems, a subsidiary of Kyocera, is teaming with the University of Tsukuba to created artificial intelligence (AI)-based technology that could identify skin cancers and other skin diseases.
Changing moles in teens
Changing moles in teensMole count in adolescents predictor of melanoma. Sun exposure habits develop in teen years. Prevent melanoma through sun protection. Reduce the number of unnecessary biopsies.
Sonidegib gets a new label for recurring laBCCSun Pharmaceutical Industries announced in September the FDA has approved a new label for sonidegib (Odomzo, Novartis), an oral hedgehog inhibitor indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or for patients who are not candidates for surgery or radiation therapy.